메타크릴산-메틸메타크릴레이트 공중합체와 락토신의 마이크로/나노 입자화

윤혜리; 이종휘; Hye Ri Yun; Jonghwi Lee

Korean Chemical Engineering Research, Vol.46, No.2, 222-226, April, 2008

Export Citation

메타크릴산-메틸메타크릴레이트 공중합체와 락토신의 마이크로/나노 입자화

Micro- and Nanoparticle Preparation of Methacrylic Acid-Methyl Methacrylate Copolymer and Lactocin

윤혜리, 이종휘 ^†

중앙대학교 화학신소재공학부, 156-756 서울시 동작구 흑석동 221

Hye Ri Yun, and Jonghwi Lee^†

Department Chemical Engineering and Materials Science, Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul 156-756, Korea

E-mail:

초록

나노입자는 생체활성물질을 지능적으로 전달하는 다양한 응용분야를 위해 개발되고 응용되어왔다. 본 연구에서는 락토신과 메타크릴산-메틸메타크릴레이트 공중합체(eudragit L100)가 나노입자로 가공되었다. 이 eudragit 고분자는 락토신을 위산으로부터 보호해주고 장에서 용출되도록 할 수 있다. 아세톤과 pH 7의 버퍼용액을 각각 비용매, 용매로 사용하였을 경우, 가장 작은 입자크기인 290 nm를 얻을 수 있었다. 얻은 입자는 분산제인 carrageenan 존재하에 동결건조를 통해, 응집을 최소화하며 건조 분말로 전환시킬 수 있었다. 락토신과 eudragit을 이용하여 얻은 일차입자는 SEM 관찰을 통해 수십나노미터크기임을 확인할 수 있었다.

Nanoparticles have been developed and applied for various applications to intelligently deliver bioactive materials. Herein, lactocin was processed into nanoparticles with methacrylic acid-methyl methacrylate copolymer (1:1) (eudragit L100). The eudragit polymer can protect lactocin from the stomach acid and release lactocin in the intestines. When acetone and pH 7 buffer solution were used as non-solvent and solvent, respectively, the smallest volume-average particle size (290 nm) could be obtained. Freeze drying in presence of carrageenan (dispersant) can process the particles into dried powders with minimum aggregation. SEM observation revealed the primary particles prepared based on lactocin and eudragit were of a few tens of nanometers.

Keywords:Nanoparticle;Microparticle;Eudragit;Lactocin;Aggregation

[References]

Lee J, J. Pharmaceutical Science, 92(10), 2057 (2003)
Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH, J. Pharmaceutical Science, 24, 441 (2005)
Eerikainen H, Kauppinen EI, Int. J. Pharm., 263, 69 (2003)
Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC, Biochemistry, 43, 3049 (2004)
Kim D, Chung M, Nutrafoods, 3(3), 11 (2004)
Devarajan PV, Sonavane GS, Drug Development and Industrial Pharmacy, 33, 101 (2007)
Kumar MNVR, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ, Chem. Rev., 104(12), 6017 (2004)
Burkhard P, Structural Biology & Biophysics, Biennial Report 2004-2005
Delie F, Blanco-Prieto MJ, Molecules, 10, 65 (2005)
Sood A, Panchagnula R, Chem. Rev., 101(11), 3275 (2001)
Fatima L, Asghar A, Chandran S, J Pharm Pharmaceut Sci., 9(3), 327 (2006)
Ogden LV, Walstra P, Morris HA, J. Diary Sci., 59(10), 1727 (1976)
Lee J, Cheng Y, J. Controlled Release, 111(1-2), 185 (2006)

[Related Articles]

[1] Lee J, J. Pharmaceutical Science, 92(10), 2057 (2003)

[2] Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH, J. Pharmaceutical Science, 24, 441 (2005)

[3] Eerikainen H, Kauppinen EI, Int. J. Pharm., 263, 69 (2003)

[4] Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC, Biochemistry, 43, 3049 (2004)

[5] Kim D, Chung M, Nutrafoods, 3(3), 11 (2004)

[6] Devarajan PV, Sonavane GS, Drug Development and Industrial Pharmacy, 33, 101 (2007)

[7] Kumar MNVR, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ, Chem. Rev., 104(12), 6017 (2004)

[8] Burkhard P, Structural Biology & Biophysics, Biennial Report 2004-2005

[9] Delie F, Blanco-Prieto MJ, Molecules, 10, 65 (2005)

[10] Sood A, Panchagnula R, Chem. Rev., 101(11), 3275 (2001)

[11] Fatima L, Asghar A, Chandran S, J Pharm Pharmaceut Sci., 9(3), 327 (2006)

[12] Ogden LV, Walstra P, Morris HA, J. Diary Sci., 59(10), 1727 (1976)

[13] Lee J, Cheng Y, J. Controlled Release, 111(1-2), 185 (2006)